Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Picks Up Drug-Delivery Technology through Alvos Acquisition

Premium

Arrowhead Research said this week that it has expanded its portfolio of drug-delivery technologies through the acquisition of privately held Alvos Therapeutics for roughly $2.1 million in stock.

According to Arrowhead, Alvos has rights to a platform of proprietary human-derived homing peptides developed by the MD Anderson Cancer Center. These targeting agents can be linked to siRNAs and small molecules to carry drugs to target cells.

Arrowhead said it plans to use the peptide technology to enhance its Rondel and dynamic polyconjugate siRNA delivery approaches.

Under the terms of the acquisition, Arrowhead bought all outstanding shares of Alvos in exchange for 315,467 shares of restricted common stock. Arrowhead's shares were trading around $6.68 midweek.

In addition, Alvos stockholders are eligible to receive additional Arrowhead stock valued at up to $23.5 million based on the achievement of clinical and regulatory milestones, including the demonstration of statistically significant efficacy in clinical trials, Arrowhead said.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.